GeoVax Labs Inc

Financials

Activos totales 10.39 M11.8 M31.35 M9.28 M8.16 M Total de pasivos 825.05 K7.44 M4.75 M3.52 M3.11 M Capital total 9.57 M4.36 M26.6 M5.76 M5.05 M Total de pasivos y patrimonio neto 10.39 M11.8 M31.35 M9.28 M8.16 M Deuda total 198.06 K0——— Deuda neta -9.69 M-11.42 M———

GeoVax is a clinical-stage biotechnology company which develops vaccines. GeoVax's development platform uses Modified Vaccinia Ankara vector technology, with improvements to antigen design and manufacturing capabilities. GeoVax uses recombinant DNA or recombinant viruses to produce virus-like particles in the person being vaccinated.

GOVX

Financials

GeoVax Labs Inc

Noticias

D. Boral Capital rebaja la calificación de las acciones de GeoVax Labs a Mantener

D. Boral Capital rebaja calificación de GeoVax Labs a mantener

D. Boral Capital downgrades GeoVax Labs stock rating to Hold

Las acciones de Tilray Brands se disparan más de un 7%; Aquí están 20 acciones que se mueven en premercado | Benzinga España

Why Tilray Brands Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket - Aclarion (NASDAQ:ACON), AXT (NASDAQ:AXTI)

Dow Gains Over 200 Points; Conagra Shares Fall After Q2 Results - Autozi Internet Tech (NASDAQ:AZI), Conagra Brands (NYSE:CAG)

GeoVax Labs, Inc. (GOVX) Q3 2025 Earnings Call Transcript

GeoVax en la Conferencia Emerging Growth: Promesa de vacuna para inmunodeprimidos

GeoVax en Conferencia de Crecimiento: Vacuna prometedora para inmunocomprometidos

GeoVax at Emerging Growth Conference: Vaccine Promise for Immunocompromised

GeoVax Labs at H.C. Wainwright: Strategic Focus on Vaccine Innovation

GeoVax Labs at Emerging Growth Conference 85: Strategic Vaccine Developments